Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Asset disposition
Quarterly results
INOVIO PHARMACEUTICALS, INC. (INO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/09/2023 8-K Quarterly results
Docs: "INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update"
07/31/2023 8-K Quarterly results
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan",
"Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan"
05/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights"
03/01/2023 8-K Quarterly results
Docs: "INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights"
01/31/2023 8-K Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates • Cost-saving measures include 11% headcount reduction • Annual savings expected to be approximately $4.3 million • Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL PLYMOUTH MEETING, PA, January 31, 2023 — INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of DNA medicines to patients. The reorganization is expected to..."
11/08/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Reports Financial Results and Highlights for the Third Quarter 2022"
08/09/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Reports Financial Results and Highlights for the Second Quarter 2022"
07/19/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
10/29/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
10/28/2021 8-K Regulation FD Disclosure  Interactive Data
06/11/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/22/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among the Company and the Representatives of the several Underwriters named therein",
"Opinion of Cooley LLP",
"INOVIO Announces Proposed Public Offering of Common Stock",
"INOVIO Announces Pricing of Public Offering of Common Stock"
01/20/2021 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Updated Corporate Disclosure",
"Updated Corporate Disclosure"
01/04/2021 8-K Quarterly results
11/16/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense PLYMOUTH MEETING, PA - November 16, 2020 - INOVIO , a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Drug Administration to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. The planned Phase 2/3 clinical trial, called INNOVATE , is a randomized, blinded, placebo-controlled safety and efficacy trial of INO-4800 to be conducted in adults in the U.S. The INNOVATE trial will b..."
10/15/2020 8-K Quarterly results
09/28/2020 8-K Quarterly results
09/03/2020 8-K Quarterly results
06/25/2020 8-K Quarterly results
06/03/2020 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 3, 2020 Inovio Pharmaceuticals, Inc. Delaware 001-14888 33-0969592 660 W. Germantown Pike, Suite 110 Plymouth Meeting, PA 19462 440-4200 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-..."
05/18/2020 8-K Submission of Matters to a Vote of Security Holders
05/12/2020 8-K Quarterly results
04/06/2020 8-K Other Events
Docs: "FORM 8-K"
04/03/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "At-The-Market Equity Offering Sales Agreement between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated",
"Opinion of Cooley LLP"
03/09/2020 8-K Quarterly results
02/07/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 1 to the At-The-Market Equity Offering Sales Agreement between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated",
"Opinion of Cooley LLP"
01/15/2020 8-K Quarterly results
01/02/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy